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The in vitro antifungal susceptibility of 636 Candida bloodstream isolates collected from 15 
tertiary hospitals in Korea was determined using the Vitek-2 yeast susceptibility system 
(bioMérieux, France). Overall susceptibility rates were 98.1%, 95.9%, 99.1%, and 97.3% 
for amphotericin B, fluconazole, voriconazole, and flucytosine, respectively. The results 
show that the rates of resistance to 4 antifungal drugs remain low among Candida blood-
stream isolates in Korea.
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The Vitek-2 yeast susceptibility system (bioMérieux, Marcy 
l’Étoile, France) is a fully automated commercial method that 
allows determination of the minimal inhibitory concentration 
(MIC) of 4 antifungal agents, i.e., amphotericin B, fluconazole, 
voriconazole, and flucytosine [1, 2]. This system has demon-
strated a high level of reproducibility and has an excellent cate-
gorical agreement with the CLSI microdilution reference method 
[1-3]. Moreover, a recent study showed that the Vitek-2 system 
is superior to the CLSI or the European Committee on Antimi-
crobial Susceptibility Testing (EUCAST) broth microdilution 
method for detecting amphotericin B-resistant Candida isolates 
[4]. Because of its advantages, including a significant reduction 
in technologist hands-on time and turnaround time [1, 2], this 
system has become one of the most widely used antifungal 
susceptibility testing systems in Korean clinical laboratories. 
However, nationwide data for the in vitro antifungal susceptibility 
of Candida bloodstream infection (BSI) isolates as determined 
by the Vitek-2 system are still lacking in Korea. In this study, we 
investigated the in vitro activity of 4 antifungal agents using the 
Vitek-2 system against Candida BSI isolates recovered from 15 
tertiary hospitals in Korea. 
 During the study period (September 2007 to August 2008), 
636 Candida BSI isolates were collected from 636 patients among 
the 15 tertiary hospitals in Korea. Antifungal susceptibility testing 
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with the Vitek-2 system was performed according to the manu-
facturer’s instructions [1, 2]. The categorical result was obtained 
according to the breakpoints provided by the Vitek-2 system for 
amphotericin B (susceptible [S], ≤1 µg/mL; intermediate, 2 µg/
mL; resistant [R], ≥4 µg/mL), fluconazole (S, ≤8 μg/mL; sus-
ceptible dose dependence [SDD], 16 to 32 μg/mL; R, ≥64 μg/
mL), and voriconazole (S, ≤1 μg/mL; SDD, 2 μg/mL; R, ≥4 μg/
mL), and flucytosine (S, ≤4 μg/mL; intermediate, 8-16 μg/mL; 
R, ≥32 μg/mL). 
 Table 1 summarizes the in vitro antifungal susceptibilities of 
the 636 Candida BSI isolates to 4 antifungal agents as deter-
mined by using the Vitek-2 system. For all 636 Candida BSI iso-
lates combined, the activity of each agent (µg/mL), expressed 
as the MIC50/MIC90 (and the percentage of susceptible isolates) 
was as follows: amphotericin, 0.5/0.5 (98.1%); fluconazole, ≤1/2 
(95.9%); voriconazole, ≤0.12/≤0.12 (99.1%); and flucytosine, 
≤1/≤1 (97.3%). These results represent the updated nation-
wide data, which show that the majority of Candida BSI isolates 
was susceptible to all 4 fungal agents tested.
 In our previous multicenter study, nearly all isolates (99.7%) 
had a MIC ≤1 µg/mL for amphotericin B [5]. In the present 
study, resistance to amphotericin B was found in 5 Candida iso-
lates; whereas intermediate resistance was found in 7 isolates. 
These Vitek-2 results produced no major errors when the E test 
Table 1. In vitro antifungal susceptibilities of 636 isolates of Candida species to fluconazole, voriconazole, amphotericin B, and flucytosine, 





SDD/I* (%) R* (%)
Range MIC50 MIC90
C. albicans (252) Amphotericin B ≤0.25-1 0.5 0.5
Fluconazole ≤1-32 ≤1 ≤1 3 (1.2)
Voriconazole ≤0.12-4 ≤0.12 ≤0.12 1 (0.4)
Flucytosine ≤1-≥64 ≤1 ≤1 8 (3.2)
C. tropicalis (149) Amphotericin B ≤0.25-0.5 ≤0.25 0.5
Fluconazole ≤1-16 ≤1 ≤1 1 (0.7)
Voriconazole ≤0.12-1 ≤0.12 ≤0.12
Flucytosine ≤1-≥64 ≤1 ≤1
C. parapsilosis (132) Amphotericin B ≤0.25-8 0.5 0.5 1 (0.8) 1 (0.8)
Fluconazole ≤1-≥64 ≤1 2 2 (1.5)
Voriconazole ≤0.12-0.5 ≤0.12 ≤0.12
Flucytosine ≤1-≥64 ≤1 ≤1 2 (1.5)
C. glabrata (72) Amphotericin B ≤0.25-8 0.5 1 6 (8.3) 2 (2.8)
Fluconazole ≤1-≥64 8 16 13 (18.1) 3 (4.2)
Voriconazole ≤0.12-8 ≤0.12 1 5 (6.9)
Flucytosine ≤1-≥64 ≤1 ≤1 1 (1.4) 1 (1.4)
Others (31)† Amphotericin B ≤0.25-≥16 ≤0.25 0.5 2 (6.5)
Fluconazole ≤1-16 2 8 4 (12.9)‡
Voriconazole ≤0.12-0.25 ≤0.12 0.25
Flucytosine ≤1-32 ≤1 8 4 (12.9) 1 (3.2)
Total (636) Amphotericin B ≤0.25-≥16 0.5 0.5 7 (1.1) 5 (0.8)
Fluconazole ≤1-≥64 ≤1 2 17 (2.7) 9 (1.4)
Voriconazole ≤0.12-8 ≤0.12 ≤0.12 6 (0.9)
Flucytosine ≤1-≥64 ≤1 ≤1 5 (0.8) 12 (1.9)
*SDD, I and R (susceptible-dose dependent, intermediate and resistant, respectively), using the Vitek-2 interpretive breakpoint criteria; †Includes Candida 
guilliermondii (10 isolates), C. famata (6 isolates), C. krusei (4 isolates), C. pelliculosa (4 isolates), C. utilis (3 isolates), C. pseudohaemulonii (2 isolates), C. 
lusitaniae (1 isolate), and C. intermedia (1 isolate); ‡All 4 C. krusei isolates are considered to be resistant to fluconazole, irrespective of the minimum inhibito-
ry concentration (MIC).
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was used as reference standard, supporting our previous report 
that Vitek-2 is more sensitive for detecting amphotericin B resis-
tance among Candida species than the CLSI method [4]. 
 According to the SENTRY Antimicrobial Surveillance Program 
[6], the percentages of Candida BSI isolates with resistance to 
fluconazole and voriconazole are 2.5% and 1.2%, respectively. 
In the present study, resistance to fluconazole was found in 
1.4% (9/636) of the Candida isolates (4 C. krusei, 3 C. glabrata, 
and 2 C. parapsilosis) and resistance to voriconazole was found 
in 0.9% (6/636) of the Candida isolates (1 C. albicans and 5 C. 
glabrata), which was comparable with our previous report [5]. 
 Until now, nationwide data on the in vitro antifungal activity of 
flucytosine against Candida BSI isolates were not available in 
Korea. Results from the global SENTRY Antimicrobial Surveil-
lance Program (2008) showed that 95.5% of the 1,201 Candida 
BSI isolates from 5 continents are susceptible to flucytosine [6]. 
Resistance to flucytosine was noted in 2.4% of C. albicans, 0% 
of C. glabrata, 0.5% of C. parapsilosis, and 10.3% of C. tropicalis 
isolates [6]. In this study, we showed, for the first time, that 
97.3% of Candida BSI isolates from Korea were susceptible to 
flucytosine, as determined by using the Vitek-2 system. Only 
3.2% of C. albicans, 1.5% of C. parapsilosis, 1.4% of C. glabrata, 
and 0% of C. tropicalis isolates were resistant to this agent. Again, 
our results show that the low rates of resistance to flucytosine 
are consistent with reports from other countries. 
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